CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
about
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapyA combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian deliveryHuman Lipocalin-Type Prostaglandin D Synthase-Based Drug Delivery System for Poorly Water-Soluble Anti-Cancer Drug SN-38Canine spontaneous glioma: a translational model system for convection-enhanced deliveryNovel treatments and therapies in development for pancreatic cancer.Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death.Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI.Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.Topoisomerase assaysEnzyme-Instructed Intracellular Molecular Self-Assembly to Boost Activity of Cisplatin against Drug-Resistant Ovarian Cancer CellsA randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles.Polymeric micellar delivery systems in oncology.Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.Dissecting Target Toxic Tissue and Tissue Specific Responses of Irinotecan in Rats Using Metabolomics Approach.Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.Lipid nanoparticles loaded with 7-ethyl-10-hydroxycamptothecin-phospholipid complex: in vitro and in vivo studies.Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples.Magnetic-Fe/Fe(3)O(4)-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages.Predicting a response to FOLFIRINOX in pancreatic cancer.Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study.In vitro conversion of irinotecan to SN-38 in human plasma.Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.Carboxylesterase 2 is downregulated in colorectal cancer following progression of the disease.Kinetic Analysis of Nanostructures Formed by Enzyme-Instructed Intracellular Assemblies against Cancer Cells.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer.
P2860
Q27851526-E49B3319-5AD4-4864-BA7A-1A1383CF6BF4Q28476831-6B958FB5-63A3-4F07-872C-C7643618F179Q28550622-13B484E0-BC1A-49D5-BE55-D931B5BF94A6Q34133134-27713BC1-52B9-4530-B9D5-D6E9775DE3DDQ34660844-3E2C8CF5-8D43-4CA9-99E3-814C8506DE8AQ34693012-A5C1712A-BC68-4CC1-947F-7E649EF0F2C9Q34968487-7C7DDF0D-286C-48B2-A9A8-64402D94C2DEQ35327883-779C9FB2-A0C3-43E4-9C37-2EBA5E4C65C0Q35677936-3642B656-697E-4B5B-B428-1068C45BF0C7Q35688543-75F92C4C-436E-4DF6-93A4-F31C6E18164FQ35827631-5EE52A29-4A05-4BB2-8DED-BB7F6F3A7BAAQ36096625-9B69B1D1-56A1-4477-AB17-A20A02CF969BQ36377590-46A9B4AA-F63D-4430-8311-3D5508C0C9C5Q36695817-988C702D-94EF-43B0-B558-ECDE0F4B4390Q36900219-4AB0B34D-138B-4A7C-BA49-322D98965020Q37319114-A5A6773D-780B-4937-B61D-EB7709E3B0EEQ37413146-6C314572-D203-40EB-ACA5-1F78D77025FFQ37441604-438C2661-1AC2-4F52-B189-10650B9CEACAQ37692023-474C30ED-423B-47B7-BB06-3199FE9122B0Q38981028-71F09114-0EF0-4EEB-8E7C-F10F8FAB6A11Q39015942-C1B79775-B61B-4FDC-AFBC-C1B20854DD85Q39454856-8DE0688B-5BFA-4D0F-ACB0-CF0D6725024AQ40016831-BB03B2DD-620D-47A1-A838-87EE2D3E6BCBQ40365203-159F1244-0E79-40C1-BC95-6F7F08E6BB6BQ42223084-38444A5B-2D7D-4B0A-8CC5-F6EE7459E920Q43215139-4E708980-735A-4B62-8E17-7341F2D974FEQ44794044-E196082C-C56A-4486-AE44-8D4C5CE40726Q44925441-09B2BB43-48DD-49CC-99CC-4FFC4B9B3FD0Q46002668-EA135CE4-9FCB-4021-9A22-678FD82BB7F3Q46764795-B59730B4-FE97-4EA0-BF6B-D9D8FD8421ACQ51734043-035B96A3-EE4E-4DE2-AFF1-3E1D2B0B3EE2Q52362144-99565D43-70E6-489D-98F8-4CD8DD0CA6CDQ53064537-E72765CF-F0DF-4F4A-8F45-8D56B8FBD127Q55252442-CBD614CA-A7F4-4F46-BDD3-8DDCA423BFAA
P2860
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
CPT-11 converting carboxyleste ...... ormal colon and liver tissues.
@ast
CPT-11 converting carboxyleste ...... ormal colon and liver tissues.
@en
type
label
CPT-11 converting carboxyleste ...... ormal colon and liver tissues.
@ast
CPT-11 converting carboxyleste ...... ormal colon and liver tissues.
@en
prefLabel
CPT-11 converting carboxyleste ...... ormal colon and liver tissues.
@ast
CPT-11 converting carboxyleste ...... ormal colon and liver tissues.
@en
P2093
P2860
P356
P1476
CPT-11 converting carboxyleste ...... ormal colon and liver tissues.
@en
P2093
E Chatelut
E Frétigny
I Hennebelle
P Chevreau
S Guichard
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690364
P407
P577
1999-05-01T00:00:00Z